Volitionrx Ltd. VNRX
Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 2015 · data as of November 13, 2026
Volitionrx Ltd. (VNRX) is a healthcare company listed in the US with a market value of about $8M. In the twelve months to September 30, 2026 it had revenue of $3M and net income of -$24M, a net margin of -698.5%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 164% a year, a 5-year average ROIC of -708%.
About Volitionrx
Volitionrx is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances, IPO year 2015. Revenue went from $14785 in 2014 to $2M in 2025, growth of about 54.2% a year. It was profitable in 0 of the last 10 years in our data. It spends 584% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3M | $2M | $1M | $775302 | $306392 | $90035 | $13433 | $17096 | — | — | — |
| Net income | -$24M | -$23M | -$27M | -$36M | -$31M | -$27M | -$20M | -$16M | -$18M | -$15M | -$12M |
| Free cash flow | -$21M | -$20M | -$26M | -$19M | -$17M | -$22M | -$18M | -$13M | -$15M | -$14M | -$9M |
| EPS (diluted) | $-0.68 | $-0.66 | $-0.93 | $-1.50 | — | $-1.53 | $-1.35 | $-1.23 | $-1.71 | $-1.68 | $-1.56 |
| Net margin | -698.5% | -1352.2% | -2186.3% | -4601.7% | -9986.7% | -29977.0% | -151900.0% | -94168.6% | — | — | — |
| ROIC | — | — | — | — | -1310.2% | -105.7% | -84.0% | -72.7% | -97.2% | -99.1% | -45.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $13.62, 5823% above the current price; targets range from $2.00 to $24.00; the consensus rating is “none”; expected EPS is $-2.00 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Volitionrx pay a dividend?
Not currently.
Is Volitionrx a good stock to buy?
We do not give buy or sell advice. Volitionrx scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.